Management of symptoms due to inoperable bowel obstruction

Tumori

Volumn 91, Issue 3, 2005, Pages 233-236

  Ripamonti, Carla ^a   Fagnoni, Elena ^a   Magni, Andrea ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Advanced cancer; Inoperable bowel obstruction; Octreotide; Symptom management

Indexed keywords

DEXAMETHASONE; ELECTROLYTE; GLUCOSE; METHADONE; METOCLOPRAMIDE; OCTREOTIDE; SCOPOLAMINE BUTYL BROMIDE;

ABDOMINAL PAIN; AGED; ARTICLE; CARCINOMATOUS PERITONITIS; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; CONTRAST RADIOGRAPHY; DROWSINESS; FEMALE; HOME CARE; HUMAN; INTESTINE DISTENSION; INTESTINE OBSTRUCTION; NAUSEA; PALLIATIVE THERAPY; VOMITING; X RAY;

EID: 23044468377     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160509100304     Document Type: Article

References (21)

1. Ripamonti C, Twycross R, Baines M, Bozzetti F, Capri S, De Conno F, Gemlo B, Hunt TM, Krebs HB, Mercadante S, Schaerer R, Wilkinson P: Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer. Support Care Cancer, 19: 23-34, 2001.
2. Feuer DJ, Broadley KE, Shepherd JH, Barton DPJ: Systematic review of surgery in malignant bowel obstruction in advanced gynecological and gastrointestinal cancer. Gynecol Oncol, 75: 313-322, 1999.
3. Ripamonti C, Mercadante S: Pathophysiology and management of malignant bowel obstruction. In: Oxford textbook of palliative medicine, 3rd edn, Doyle D, Hanks, GW, McDonald N, Cherny N (Eds), pp 496-506, Oxford University Press, New York, 2004.
4. Baines M, Oliver DJ, Carter RL: Medical management of intestinal obstruction in patients with advanced malignant disease: a clinical and pathological study. Lancet, 2: 990-993, 1985.
5. Fainsinger RL, Spachynski K, Hanson J: Symptom control in terminally ill patients with malignant bowel obstruction. J Pain Symp Manag, 9: 12-18, 1994.
6. World Health Organization: Cancer pain relief. Geneva, Switzerland, World Health Organization, 1986.
7. Mercadante S, Sapio M, Serretta R: Treatment of pain in chronic bowel subobstruction with self-administration of methadone. Support Care Cancer, 5: 327-329, 1997.
8. Mercadante S, Casuccio A, Fulfaro F, Groff L, Boffi R, Villari P: Switching from morphine to metadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol, 19: 2898-2904, 2001.
9. Ripamonti C, Panzeri C, Groff L, Galeazzi G, Boffi R: The role of somatostatin and octreotide in bowel obstruction: preclinical and clinical results. Tumori, 87: 1-9, 2001.
10. Ripamonti C, Mercadante S: How to use octreotide for malignant bowel obstruction. J Support Oncol, 2: 1-8, 2004. www.SupportiveOncology.net
11. Nellgard P, Bojo L, Cassuto J: Importance of vasoactive intestinal peptide and somatostatin for fluid losses in small-bowel obstruction. Scan J Gastroenterol, 30: 464-469, 1995.
12. Fallon MT: The physiology of somatostatin and its synthetic analogue, octreotide. Eur J Palliat Care, 1: 20-22, 1994.
13. Mercadante S: Scopolamine butylbromide plus octreotide in unresponsive bowel obstruction. J Pain Symp Manag, 16: 278-279, 1998.
14. Ripamonti C, Mercadante S, Groff L, Zecca E, De Conno F, Casuccio A: Role of octreotide, scopolamine butylbromide and hydration in symptom control of patients with inoperable bowel obstruction having a nasogastric tube. A prospective, randomized clinical trial. J Pain Symp Manag, 19: 23-34, 2000.
15. Mercadante S, Ripamonti C, Casuccio A, Zecca E, Groff L: Comparison of octreotide and hyoscine butylbromide in conbowel xgastrointestinal symptoms due to malignant inoperable bowel obstruction. Support Care Cancer, 8: 188-191, 2000.
16. Mystakidou K, Tsilika E, Kalaidopoulou O, Chondros K, Georgaki S, Papadimitriou L: Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double-blind, controlled clinical trial. Anticancer Res, 22: 1187-1192, 2002.
17. Mercadante S, Avola G, Maddaloni S, Salamone G, Aragona F, Rodolico V: Octreotide prevents the pathological alterations of bowel obstruction in cancer patients. Support Care Cancer, 4: 393-394, 1996.
18. Mercadante S, Kargar J, Nicolosi G: Octreotide may prevent definitive intestinal obstruction. J Pain Symp Manag, 13: 352-355, 1997.
19. Mercadante S, Ferrera P, Villari P, Marrazzo A: Aggressive pharmacolgical treatment for reversing bowel obstruction. J Pain Symp Manag, 28: 412-416, 2004.
20. Fainsinger RL, MacEachern T, Miller MJ: The use of hypodermoclysis for rehydration in terminally ill cancer patients. J Pain Symp Manag, 9: 298-302, 1994.
21. Fainsinger RL: Hydration. In: Gastrointestinal symptoms in advanced cancer patients, Ripamonti C, Bruera E (Eds), vol 22, pp 395-410, Oxford University Press, Oxford, 2002.